Subscribe to RSS
DOI: 10.1055/s-0041-1729885
The Growing Impact of Cardiovascular Oncology: Epidemiology and Pathophysiology
![](https://www.thieme-connect.de/media/sth/202108/lookinside/thumbnails/10-1055-s-0041-1729885_02896-1.jpg)
Abstract
Progress in the treatment of cancer has significantly improved survival of oncologic patients in recent decades. However, anticancer therapies, particularly some new, more potent and targeted agents, are potentially cardiotoxic. As a consequence, cardiovascular complications, including heart failure, arterial hypertension, coronary artery disease, venous thromboembolism, peripheral vascular disease, arrhythmias, pericardial disease, and pulmonary hypertension, as related to cancer itself or to anticancer treatments, are increasingly observed and may adversely affect prognosis in oncologic patients. Cardiovascular oncology is an emerging field in cardiology and internal medicine, which is rapidly growing, dealing with the prevention, the early detection, and the management of cardiovascular disease, in all stages of anticancer therapy and during the survivorship period, now crucial for reducing cardiovascular morbidity and mortality in cancer patients. In this narrative review, the existing literature regarding the epidemiology of cardiovascular oncology, the mechanisms of cardiovascular complications in cancer, and the pathophysiology of cardiotoxicity related to chemotherapeutic agents, targeted therapies, immunotherapies, and radiotherapy will be analyzed and summarized.
Publication History
Article published online:
12 July 2021
© 2021. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Zamorano JL, Lancellotti P, Rodriguez Muñoz D. et al; ESC Scientific Document Group. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 2016; 37 (36) 2768-2801
- 2 Koutsoukis A, Ntalianis A, Repasos E, Kastritis E, Dimopoulos MA, Paraskevaidis I. Cardio-oncology: a focus on cardiotoxicity. Eur Cardiol 2018; 13 (01) 64-69
- 3 Farmakis D, Parissis J, Filippatos G. Insights into onco-cardiology: atrial fibrillation in cancer. J Am Coll Cardiol 2014; 63 (10) 945-953
- 4 Howard E, Steingart RM, Armstrong GT. et al. Cardiovascular events in cancer survivors. Semin Oncol 2019; 46 (06) 426-432
- 5 Larsen CM, Mulvagh SL. Cardio-oncology: what you need to know now for clinical practice and echocardiography. Echo Res Pract 2017; 4 (01) R33-R41
- 6 Curigliano G, Cardinale D, Suter T. et al; ESMO Guidelines Working Group. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol 2012; 23 (Suppl. 07) vii155-vii166
- 7 Plana JC, Galderisi M, Barac A. et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2014; 15 (10) 1063-1093
- 8 Armenian SH, Lacchetti C, Barac A. et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2017; 35 (08) 893-911
- 9 Lancellotti P, Nkomo VT, Badano LP. et al; European Society of Cardiology Working Groups on Nuclear Cardiology and Cardiac Computed Tomography and Cardiovascular Magnetic Resonance, American Society of Nuclear Cardiology, Society for Cardiovascular Magnetic Resonance, Society of Cardiovascular Computed Tomography. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Eur Heart J Cardiovasc Imaging 2013; 14 (08) 721-740
- 10 Markman TM, Markman M. Cardio-oncology: mechanisms of cardiovascular toxicity. F1000 Res 2018; 7: 113
- 11 Pudil R. The future role of cardio-oncologists. Card Fail Rev 2017; 3 (02) 140-142
- 12 Curigliano G, Cardinale D, Dent S. et al. Cardiotoxicity of anticancer treatments: epidemiology, detection, and management. CA Cancer J Clin 2016; 66 (04) 309-325
- 13 Narayan V, Ky B. Common cardiovascular complications of cancer therapy: epidemiology, risk prediction, and prevention. Annu Rev Med 2018; 69 (69) 97-111
- 14 Von Hoff DD, Layard MW, Basa P. et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91 (05) 710-717
- 15 Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 2009; 53 (24) 2231-2247
- 16 Simůnek T, Stérba M, Popelová O, Adamcová M, Hrdina R, Gersl V. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep 2009; 61 (01) 154-171
- 17 Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 2005; 23 (13) 2900-2902
- 18 de Azambuja E, Bedard PL, Suter T, Piccart-Gebhart M. Cardiac toxicity with anti-HER-2 therapies: what have we learned so far?. Target Oncol 2009; 4 (02) 77-88
- 19 Hahn VS, Lenihan DJ, Ky B. Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies. [serial online] J Am Heart Assoc 2014; 3 (02) e000665
- 20 Qi WX, Shen Z, Tang LN, Yao Y. Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials. Br J Clin Pharmacol 2014; 78 (04) 748-762
- 21 Narayan V, Keefe S, Haas N. et al. Prospective evaluation of sunitinib-induced cardiotoxicity in patients with metastatic renal cell carcinoma. Clin Cancer Res 2017; 23 (14) 3601-3609
- 22 Ghatalia P, Morgan CJ, Je Y. et al. Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Crit Rev Oncol Hematol 2015; 94 (02) 228-237
- 23 Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007; 7 (05) 332-344
- 24 de Jesus-Gonzalez N, Robinson E, Moslehi J, Humphreys BD. Management of antiangiogenic therapy-induced hypertension. Hypertension 2012; 60 (03) 607-615
- 25 Izzedine H, Massard C, Spano JP, Goldwasser F, Khayat D, Soria JC. VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management. Eur J Cancer 2010; 46 (02) 439-448
- 26 Johnson DB, Balko JM, Compton ML. et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 2016; 375 (18) 1749-1755
- 27 Jain V, Bahia J, Mohebtash M, Barac A. Cardiovascular complications associated with novel cancer immunotherapies. Curr Treat Options Cardiovasc Med 2017; 19 (05) 36
- 28 Zarifa A, Albittar A, Kim PY. et al. Cardiac toxicities of anticancer treatments: chemotherapy, targeted therapy and immunotherapy. Curr Opin Cardiol 2019; 34 (04) 441-450
- 29 Grandin EW, Ky B, Cornell RF, Carver J, Lenihan DJ. Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma. J Card Fail 2015; 21 (02) 138-144
- 30 Willis MS, Patterson C. Proteotoxicity and cardiac dysfunction--Alzheimer's disease of the heart?. N Engl J Med 2013; 368 (05) 455-464
- 31 Siegel D, Martin T, Nooka A. et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica 2013; 98 (11) 1753-1761
- 32 Jaworski C, Mariani JA, Wheeler G, Kaye DM. Cardiac complications of thoracic irradiation. J Am Coll Cardiol 2013; 61 (23) 2319-2328
- 33 Hooning MJ, Botma A, Aleman BM. et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst 2007; 99 (05) 365-375
- 34 Kosmas C, Kallistratos MS, Kopterides P. et al. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol 2008; 134 (01) 75-82
- 35 Polk A, Vistisen K, Vaage-Nilsen M, Nielsen DL. A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity. BMC Pharmacol Toxicol 2014; 15: 47
- 36 Donnellan E, Khorana AA. Cancer and venous thromboembolic disease: a review. Oncologist 2017; 22 (02) 199-207
- 37 Ay C, Pabinger I, Cohen AT. Cancer-associated venous thromboembolism: burden, mechanisms, and management. Thromb Haemost 2017; 117 (02) 219-230
- 38 Nasser NJ, Fox J, Agbarya A. Potential mechanisms of cancer-related hypercoagulability. Cancers (Basel) 2020; 12 (03) 566
- 39 Labianca A, Bosetti T, Indini A, Negrini G, Labianca RF. Risk prediction and new prophylaxis strategies for thromboembolism in cancer. Cancers (Basel) 2020; 12 (08) E2070
- 40 Kim AS, Khorana AA, McCrae KR. Mechanisms and biomarkers of cancer-associated thrombosis. Transl Res 2020; 225: 33-53
- 41 Fisher B, Dignam J, Wolmark N. et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 1997; 89 (22) 1673-1682
- 42 Seng S, Liu Z, Chiu SK. et al. Risk of venous thromboembolism in patients with cancer treated with cisplatin: a systematic review and meta-analysis. J Clin Oncol 2012; 30 (35) 4416-4426
- 43 Gugliotta L, Mazzucconi MG, Leone G. et al; The GIMEMA Group. Incidence of thrombotic complications in adult patients with acute lymphoblastic leukaemia receiving L-asparaginase during induction therapy: a retrospective study. Eur J Haematol 1992; 49 (02) 63-66
- 44 Caruso V, Iacoviello L, Di Castelnuovo A. et al. Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood 2006; 108 (07) 2216-2222
- 45 Cabanillas ME, Schlumberger M, Jarzab B. et al. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: a clinical outcomes and biomarker assessment. Cancer 2015; 121 (16) 2749-2756
- 46 Prandoni P, Lensing AW, Piccioli A. et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100 (10) 3484-3488
- 47 Weitz JI, Haas S, Ageno W. et al; GARFIELD-VTE Investigators. Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE. J Thromb Thrombolysis 2020; 50 (02) 267-277
- 48 Key NS, Khorana AA, Kuderer NM. et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Clinical Practice Guideline update. J Clin Oncol 2020; 38 (05) 496-520
- 49 Lenihan DJ, Kowey PR. Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors. Oncologist 2013; 18 (08) 900-908
- 50 Mery B, Guichard JB, Guy JB. et al. Atrial fibrillation in cancer patients: hindsight, insight and foresight. Int J Cardiol 2017; 240: 196-202
- 51 López-Fernández T, Martín-García A, Roldán Rabadán I. et al; Expert Reviewers. Atrial fibrillation in active cancer patients: expert position paper and recommendations. Rev Esp Cardiol (Engl Ed) 2019; 72 (09) 749-759
- 52 Tufano A, Galderisi M, Esposito L. et al. Anticancer drug-related nonvalvular atrial fibrillation: challenges in management and antithrombotic strategies. Semin Thromb Hemost 2018; 44 (04) 388-396
- 53 Imperatori A, Mariscalco G, Riganti G, Rotolo N, Conti V, Dominioni L. Atrial fibrillation after pulmonary lobectomy for lung cancer affects long-term survival in a prospective single-center study. J Cardiothorac Surg 2012; 7: 4
- 54 Onaitis M, D'Amico T, Zhao Y, O'Brien S, Harpole D. Risk factors for atrial fibrillation after lung cancer surgery: analysis of the Society of Thoracic Surgeons general thoracic surgery database. Ann Thorac Surg 2010; 90 (02) 368-374
- 55 O'Neal WT, Lakoski SG, Qureshi W. et al. Relation between cancer and atrial fibrillation (from the REasons for Geographic And Racial Differences in Stroke Study). Am J Cardiol 2015; 115 (08) 1090-1094
- 56 Ostenfeld EB, Erichsen R, Pedersen L, Farkas DK, Weiss NS, Sørensen HT. Atrial fibrillation as a marker of occult cancer. PLoS One 2014; 9 (08) e102861
- 57 Erichsen R, Christiansen CF, Mehnert F, Weiss NS, Baron JA, Sørensen HT. Colorectal cancer and risk of atrial fibrillation and flutter: a population-based case-control study. Intern Emerg Med 2012; 7 (05) 431-438
- 58 Glanzmann C, Huguenin P, Lütolf UM, Maire R, Jenni R, Gumppenberg V. Cardiac lesions after mediastinal irradiation for Hodgkin's disease. Radiother Oncol 1994; 30 (01) 43-54
- 59 Montani D, Bergot E, Günther S. et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012; 125 (17) 2128-2137
- 60 Ranchoux B, Günther S, Quarck R. et al. Chemotherapy-induced pulmonary hypertension: role of alkylating agents. Am J Pathol 2015; 185 (02) 356-371
- 61 Herrmann J. Vascular toxic effects of cancer therapies. Nat Rev Cardiol 2020; 17 (08) 503-522
- 62 Guignabert C, Phan C, Seferian A. et al. Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. J Clin Invest 2016; 126 (09) 3207-3218
- 63 Weatherald J, Chaumais MC, Montani D. Pulmonary arterial hypertension induced by tyrosine kinase inhibitors. Curr Opin Pulm Med 2017; 23 (05) 392-397
- 64 Weatherald J, Chaumais MC, Savale L. et al. Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study. Eur Respir J 2017; 50 (01) 1700217
- 65 Ala CK, Klein AL, Moslehi JJ. Cancer treatment-associated pericardial disease: epidemiology, clinical presentation, diagnosis, and management. Curr Cardiol Rep 2019; 21 (12) 156
- 66 Tan-Chiu E, Yothers G, Romond E. et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005; 23 (31) 7811-7819
- 67 Markman TM, Markman M. Cardio-oncology: management of cardiovascular toxicity. F1000 Res 2019; 8: 120
- 68 Carrier M, Abou-Nassar K, Mallick R. et al; AVERT Investigators. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med 2019; 380 (08) 711-719
- 69 Khorana AA, Soff GA, Kakkar AK. et al; CASSINI Investigators. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med 2019; 380 (08) 720-728